Predicting Opportunity in Emerging Therapies

The advent of groundbreaking therapies in the metabolic sector, including GLP-1, offers substantial opportunities for pharmaceutical companies, yet accurately estimating the size of these emerging markets, marked by significant unmet clinical needs, presents distinct challenges.

The emergence of novel therapies, particularly in the metabolic space, presents valuable opportunities for drug manufacturers, who have strategically invested in these areas. However, accurately sizing these nascent markets, often characterised by well-documented unmet clinical needs, poses unique challenges. 

This paper, "Predicting Opportunity in Emerging Therapies: Market Sizing Insights from the GLP-1 and Metabolic Arena," explores these challenges using the glucagon-like peptide-1 (GLP-1) market as a prime example. It highlights the importance of a comprehensive approach to market sizing, moving beyond epidemiological data to incorporate prescription rates, access considerations, stakeholder perceptions, and real-world treatment data.

The paper provides valuable guidance for navigating these complex markets, emphasising the need for robust primary market research, expert consultation, and a deep understanding of stakeholder perceptions. By addressing potential pitfalls and offering practical strategies, this paper equips manufacturers with the tools to confidently evaluate opportunities and make informed decisions in these evolving therapeutic areas.

 

Ipsos’ GLP-1 Market Sizing Study, which gauges caseload and GLP-1 volume usage across a variety of clinician stakeholders, will be available in Q4 ’24. Contact Ramya Logendra to learn more.

Download

The author(s)

  • Jesse Cuaron
    PhD, PPM - Associate Vice President, Forecasting and CI at Ipsos

More insights about Health

Related news

  • KEYS: Our World in Motion
    E mobility Webinar

    [Webinar] KEYS: Our World in Motion

    At our next KEYS webinar, we’ll be launching the inaugural Ipsos Mobility Report.
  • [Webinar] Real evidence from real experiences: Patient Centric Evidence
    Healthcare Webinar

    [Webinar] Real evidence from real experiences: Patient Centric Evidence

    Regulators, payers and clinicians are asking for more than traditional real world evidence (RWE). They want to understand how treatments affect people’s daily lives - not just what is written in the case report form. But how can you build patient-centric evidence that stands up to scientific, regulatory and commercial scrutiny?
  • Battle For Attention - KEYS Webinar from Ipsos
    Communications Events replay

    [Webinar] KEYS: Battle For Attention

    In today’s hyper-fragmented landscape, communicating using short-form content and social media platforms is an essential part of our toolkit. But are they better suited to short-term engagement rather than long-term brand building? And what does genuinely innovative and creative advertising look like these days?